United Therapeutics Set to Announce Q4 Earnings on February 25
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy UTHR?
Source: seekingalpha
- Earnings Announcement: United Therapeutics is set to release its Q4 earnings results on February 25 before the market opens, with investors keenly awaiting performance metrics to gauge future growth potential.
- EPS Expectations: The consensus EPS estimate stands at $7.24, indicating investor focus on profitability, although recent EPS estimates have seen no upward revisions and one downward revision, reflecting mixed market sentiment.
- Revenue Forecast Analysis: The revenue estimate is $811.35 million, representing a 10.3% year-over-year increase; however, in the last three months, revenue estimates have experienced one upward revision and four downward revisions, suggesting cautious market outlook on revenue growth.
- Market Reaction: Investors will closely monitor the upcoming earnings report from United Therapeutics to assess the company's competitiveness in the biopharmaceutical sector and its strategic direction moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UTHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to rise
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 474.520
Low
423.00
Averages
534.50
High
645.00
Current: 474.520
Low
423.00
Averages
534.50
High
645.00
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
United Therapeutics Set to Announce Q4 Earnings on February 25
- Earnings Announcement: United Therapeutics is set to release its Q4 earnings results on February 25 before the market opens, with investors keenly awaiting performance metrics to gauge future growth potential.
- EPS Expectations: The consensus EPS estimate stands at $7.24, indicating investor focus on profitability, although recent EPS estimates have seen no upward revisions and one downward revision, reflecting mixed market sentiment.
- Revenue Forecast Analysis: The revenue estimate is $811.35 million, representing a 10.3% year-over-year increase; however, in the last three months, revenue estimates have experienced one upward revision and four downward revisions, suggesting cautious market outlook on revenue growth.
- Market Reaction: Investors will closely monitor the upcoming earnings report from United Therapeutics to assess the company's competitiveness in the biopharmaceutical sector and its strategic direction moving forward.
See More
Tom Gardner Discusses AI and Investment Strategies
- Rise of AI Native Companies: Tom Gardner emphasizes that future winners will be AI native companies that fully integrate AI into their culture, enabling them to achieve higher productivity with fewer employees, thus gaining a competitive edge.
- Market Indicator Analysis: Gardner utilizes the Potential Growth Indicator and Market View Tool to guide investment decisions, with the former indicating potential market overvaluation and expected annual returns between 8.5% and 9%, while the latter forecasts closer to 10.5%, reflecting the market's complexity.
- Portfolio Strategy: Gardner stresses that investors should adopt an incremental strategy, focusing on cash inflows into the market to avoid significant losses during market volatility, particularly for those nearing retirement who need to manage their assets cautiously.
- Stock Recommendations for the Next Five Years: He recommends six stocks, including TransMedics, which is expected to triple in value over the next 6-7 years, and Aritzia, which shows strong financial management and growth potential in the U.S. market.
See More
United Therapeutics Reports Positive Phase 1 Results for MiroliverELAP
- Clinical Trial Success: In a Phase 1 study for acute liver failure, five patients treated with miroliverELAP for at least 44 hours met the survival endpoint, demonstrating the product's potential to provide critical liver support in dire situations.
- Safety Assessment Positive: No unexpected serious adverse events were reported during a subsequent 32-day follow-up, indicating the safety of miroliverELAP in clinical applications and laying the groundwork for future commercialization.
- Future Research Plans: Full study results are expected to be published in the second half of 2026, further validating the efficacy and safety of miroliverELAP, which could drive its market adoption.
- Stable Stock Performance: United Therapeutics' stock has increased approximately 26.89% over the past 12 months, currently trading at $471, reflecting relatively strong market performance despite facing some technical pressure in the short term.
See More
United Therapeutics Upgraded to Overweight with Price Target of $535.73
- Rating Upgrade: United Therapeutics (UTHR) has received an upgrade to an overweight rating, reflecting analysts' optimistic expectations for its future performance, which may attract more investor attention.
- Price Target Set: Analysts have set a price target of $535.73, indicating confidence in the company's growth potential, which could drive the stock price towards this target.
- Market Reaction: The upgrade in rating and price target may enhance market confidence in United Therapeutics, potentially increasing the liquidity and attractiveness of its stock.
- Investor Strategy: By raising the rating and price target, analysts may aim to guide investors to reassess the investment value of United Therapeutics, thereby enhancing its competitiveness in the biopharmaceutical sector.
See More
WYNN Options Volume Surges 148.3% with 19,101 Contracts Traded
- Surge in Options Volume: Wynn Resorts (WYNN) has seen an options trading volume of 19,101 contracts today, equivalent to approximately 1.9 million shares, which represents a significant 148.3% of its average daily trading volume over the past month, indicating heightened market interest in the stock.
- High-Frequency Trading Insight: Among all contracts, the $110 strike call option expiring on March 20, 2026, stands out with 15,632 contracts traded, representing about 1.6 million shares, suggesting that investors are increasingly optimistic about future price increases.
- Market Dynamics Observation: In comparison, Vanda Pharmaceuticals (VNDA) also exhibited strong options trading today with 22,662 contracts, equivalent to approximately 2.3 million shares, reflecting 147.5% of its average daily trading volume over the past month, highlighting market interest in the biotech sector.
- Investor Sentiment Analysis: VNDA's $8 strike call option has also gained traction with a trading volume of 4,435 contracts, representing about 443,500 shares, indicating a bullish sentiment among investors regarding the company's future performance, which could drive its stock price higher.
See More
S&P 500 Futures Steady in Pre-Market Session; United Therapeutics and Intel Underperform
Stock Market Opening: U.S. stock markets are set to open in two hours.
UiPath Inc. Performance: UiPath Inc. (PATH) saw an increase of 8.1% in pre-market trading.
CCC Intelligent Solutions Holdings Inc. Performance: CCC Intelligent Solutions Holdings Inc. (CCC) experienced a rise of 4.4% in pre-market trading.
See More
United Therapeutics Set to Announce Q4 Earnings on February 25
- Earnings Announcement: United Therapeutics is set to release its Q4 earnings results on February 25 before the market opens, with investors keenly awaiting performance metrics to gauge future growth potential.
- EPS Expectations: The consensus EPS estimate stands at $7.24, indicating investor focus on profitability, although recent EPS estimates have seen no upward revisions and one downward revision, reflecting mixed market sentiment.
- Revenue Forecast Analysis: The revenue estimate is $811.35 million, representing a 10.3% year-over-year increase; however, in the last three months, revenue estimates have experienced one upward revision and four downward revisions, suggesting cautious market outlook on revenue growth.
- Market Reaction: Investors will closely monitor the upcoming earnings report from United Therapeutics to assess the company's competitiveness in the biopharmaceutical sector and its strategic direction moving forward.
See More
Tom Gardner Discusses AI and Investment Strategies
- Rise of AI Native Companies: Tom Gardner emphasizes that future winners will be AI native companies that fully integrate AI into their culture, enabling them to achieve higher productivity with fewer employees, thus gaining a competitive edge.
- Market Indicator Analysis: Gardner utilizes the Potential Growth Indicator and Market View Tool to guide investment decisions, with the former indicating potential market overvaluation and expected annual returns between 8.5% and 9%, while the latter forecasts closer to 10.5%, reflecting the market's complexity.
- Portfolio Strategy: Gardner stresses that investors should adopt an incremental strategy, focusing on cash inflows into the market to avoid significant losses during market volatility, particularly for those nearing retirement who need to manage their assets cautiously.
- Stock Recommendations for the Next Five Years: He recommends six stocks, including TransMedics, which is expected to triple in value over the next 6-7 years, and Aritzia, which shows strong financial management and growth potential in the U.S. market.
See More
United Therapeutics Reports Positive Phase 1 Results for MiroliverELAP
- Clinical Trial Success: In a Phase 1 study for acute liver failure, five patients treated with miroliverELAP for at least 44 hours met the survival endpoint, demonstrating the product's potential to provide critical liver support in dire situations.
- Safety Assessment Positive: No unexpected serious adverse events were reported during a subsequent 32-day follow-up, indicating the safety of miroliverELAP in clinical applications and laying the groundwork for future commercialization.
- Future Research Plans: Full study results are expected to be published in the second half of 2026, further validating the efficacy and safety of miroliverELAP, which could drive its market adoption.
- Stable Stock Performance: United Therapeutics' stock has increased approximately 26.89% over the past 12 months, currently trading at $471, reflecting relatively strong market performance despite facing some technical pressure in the short term.
See More
United Therapeutics Upgraded to Overweight with Price Target of $535.73
- Rating Upgrade: United Therapeutics (UTHR) has received an upgrade to an overweight rating, reflecting analysts' optimistic expectations for its future performance, which may attract more investor attention.
- Price Target Set: Analysts have set a price target of $535.73, indicating confidence in the company's growth potential, which could drive the stock price towards this target.
- Market Reaction: The upgrade in rating and price target may enhance market confidence in United Therapeutics, potentially increasing the liquidity and attractiveness of its stock.
- Investor Strategy: By raising the rating and price target, analysts may aim to guide investors to reassess the investment value of United Therapeutics, thereby enhancing its competitiveness in the biopharmaceutical sector.
See More
WYNN Options Volume Surges 148.3% with 19,101 Contracts Traded
- Surge in Options Volume: Wynn Resorts (WYNN) has seen an options trading volume of 19,101 contracts today, equivalent to approximately 1.9 million shares, which represents a significant 148.3% of its average daily trading volume over the past month, indicating heightened market interest in the stock.
- High-Frequency Trading Insight: Among all contracts, the $110 strike call option expiring on March 20, 2026, stands out with 15,632 contracts traded, representing about 1.6 million shares, suggesting that investors are increasingly optimistic about future price increases.
- Market Dynamics Observation: In comparison, Vanda Pharmaceuticals (VNDA) also exhibited strong options trading today with 22,662 contracts, equivalent to approximately 2.3 million shares, reflecting 147.5% of its average daily trading volume over the past month, highlighting market interest in the biotech sector.
- Investor Sentiment Analysis: VNDA's $8 strike call option has also gained traction with a trading volume of 4,435 contracts, representing about 443,500 shares, indicating a bullish sentiment among investors regarding the company's future performance, which could drive its stock price higher.
See More
S&P 500 Futures Steady in Pre-Market Session; United Therapeutics and Intel Underperform
Stock Market Opening: U.S. stock markets are set to open in two hours.
UiPath Inc. Performance: UiPath Inc. (PATH) saw an increase of 8.1% in pre-market trading.
CCC Intelligent Solutions Holdings Inc. Performance: CCC Intelligent Solutions Holdings Inc. (CCC) experienced a rise of 4.4% in pre-market trading.
See More
